Impact of Chemotherapy Regimens on Breast Cancer Response
Author Information
Author(s): Soong June Bae, Jee Hung Kim, Min Ji Kim, Kook Yoonwon, Baek Seung Ho, Kim Jung Hyun, Moon Sohyun, Lee Seung Eun, Jeong Joon, Cha Yoon Jin, Ahn Sung Gwe
Primary Institution: Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
Hypothesis
Does the addition of carboplatin and pembrolizumab to neoadjuvant chemotherapy improve pathologic complete response rates in triple-negative breast cancer patients?
Conclusion
The addition of pembrolizumab significantly increased the pathologic complete response rate in lymphocyte-predominant breast cancer, while carboplatin improved response in non-lymphocyte-predominant cases.
Supporting Evidence
- Pathologic complete response rates were 32% in non-carboplatin, 57% in carboplatin, and 64% in pembrolizumab groups.
- 20.4% of patients had lymphocyte-predominant breast cancer.
- High levels of stromal tumor-infiltrating lymphocytes were correlated with higher pCR rates.
Takeaway
This study looked at how different chemotherapy treatments help patients with a type of breast cancer called triple-negative. It found that adding certain medicines can help more patients get better.
Methodology
A retrospective cohort study analyzing 450 TNBC patients treated with neoadjuvant chemotherapy and evaluating sTIL levels.
Potential Biases
Potential biases in patient selection and retrospective data collection.
Limitations
The study had a relatively small cohort for the pembrolizumab group and did not analyze survival outcomes due to recent treatment.
Participant Demographics
Among the 450 patients, 41.4% were aged ≥50 years, and 41.8% had histologic grade III tumors.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 1.64–4.57 for carboplatin; 95% CI, 2.20–7.16 for pembrolizumab
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website